<div id="readability-page-1"><p>Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) posted its earnings results on Thursday. The company reported ($2.28) EPS for the quarter, beating analysts' consensus estimates of ($2.94) by $0.66, Zacks reports.</p><div><p><span></span><span>Get <strong>Inhibrx Biosciences</strong> alerts:</span></p></div><h2>Inhibrx Biosciences Trading Up 6.0%</h2><p>Inhibrx Biosciences stock traded up $4.51 during trading on Friday, hitting $79.13. The company's stock had a trading volume of 600,093 shares, compared to its average volume of 766,212. The stock's fifty day moving average is $45.90 and its 200 day moving average is $27.91. Inhibrx Biosciences has a 1-year low of $10.81 and a 1-year high of $86.64. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -7.48 and a beta of 1.09. The company has a debt-to-equity ratio of 1.45, a quick ratio of 4.98 and a current ratio of 4.98. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several research firms have commented on INBX. Wall Street Zen upgraded shares of Inhibrx Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Sunday, August 17th. JMP Securities  reaffirmed a &#34;market perform&#34; rating on shares of Inhibrx Biosciences in a research report on Friday, August 22nd. Finally, Weiss Ratings  reissued a &#34;sell (d)&#34; rating on shares of Inhibrx Biosciences in a report on Wednesday, October 8th. One analyst  has rated the stock with a Hold rating and one  has issued  a Sell rating to the stock. According to data from MarketBeat, Inhibrx Biosciences currently has an average rating of &#34;Reduce&#34;.</p><p><b>Read Our Latest Analysis on INBX</b></p><h2>Insider Buying and Selling at Inhibrx Biosciences</h2><p>In related news, major shareholder Global Investors Lp Viking sold 350,000 shares of Inhibrx Biosciences stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $32.25, for a total transaction of $11,287,500.00. Following the transaction, the insider owned 67,018 shares in the company, valued at approximately $2,161,330.50. The trade was a 83.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own  17.09% of the company's stock. </p><h2>Institutional Trading of Inhibrx Biosciences</h2><p>Several institutional investors and hedge funds have recently bought and sold shares of INBX. Caligan Partners LP bought a new stake in shares of  Inhibrx Biosciences in the 3rd quarter worth approximately $7,961,000.  SummitTX Capital L.P. bought a new stake in  Inhibrx Biosciences in the 3rd quarter valued at about $1,824,000.  Bridgeway Capital Management LLC acquired a new position in  Inhibrx Biosciences during the 2nd quarter valued at about $235,000.  Acuta Capital Partners LLC bought a new position in  Inhibrx Biosciences in the 3rd quarter worth about $552,000.  Finally, Invesco Ltd. acquired a new stake in shares of  Inhibrx Biosciences in the second quarter valued at approximately $193,000. Institutional investors and hedge funds own  82.46% of the company's stock. </p><h2>Inhibrx Biosciences Company Profile</h2> (Get Free Report)<p>Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Inhibrx Biosciences</li><li>Trading Stocks: RSI and Why it's Useful</li><li>Are These 3 Oversold Tech Giants Ready to Rebound?</li><li>What is a buyback in stocks? A comprehensive guide for investors</li><li>If You Wait for the Dip,  Micron Technology Could Leave You Behind</li><li>3 Grocery Stocks That Are Proving They Are Still Essential </li><li>3 Stocks Quietly Powering the AI and Tech Revolution</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5CWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5CWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Inhibrx Biosciences Right Now?</h2><p>Before you consider Inhibrx Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx Biosciences wasn't on the list.</p><p>While Inhibrx Biosciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

INBX

<p>Inhibrx Biosciences (NASDAQ:INBX) announced its quarterly earnings, reporting a loss of $2.28 per share, beating the consensus estimate of $2.94 loss. The stock rose 6.0% to $79.13. The company has a market cap of $1.15 billion and a debt-to-equity ratio of 1.45. Analysts have mixed ratings on the stock. Major shareholder Global Investors Lp Viking sold 350,000 shares. Institutional investors own 82.46% of the company's stock.</p>

Inhibrx Biosciences (NASDAQ:INBX) Issues Earnings Results